Axial
@axial.bsky.social
Agency for great inventors https://linktr.ee/axialxyz
"Successful biotech companies are created from a special alchemy of science, business, technology, talent, and capital”
- Carl Hansen, Founder and CEO of AbCellera
- Carl Hansen, Founder and CEO of AbCellera
May 9, 2024 at 6:55 PM
"Successful biotech companies are created from a special alchemy of science, business, technology, talent, and capital”
- Carl Hansen, Founder and CEO of AbCellera
- Carl Hansen, Founder and CEO of AbCellera
Reposted by Axial
Let the Best Drug Win with Errik Anderson axial.substack.com/p/let-the-be...
Errik Anderson is the CEO and Founder of Alloy Therapeutics. Founded in 2017, the company democratizes access to drug discovery platforms and services. In our conversation, we discuss Alloy's product offering and story
Errik Anderson is the CEO and Founder of Alloy Therapeutics. Founded in 2017, the company democratizes access to drug discovery platforms and services. In our conversation, we discuss Alloy's product offering and story
January 4, 2024 at 6:29 PM
Let the Best Drug Win with Errik Anderson axial.substack.com/p/let-the-be...
Errik Anderson is the CEO and Founder of Alloy Therapeutics. Founded in 2017, the company democratizes access to drug discovery platforms and services. In our conversation, we discuss Alloy's product offering and story
Errik Anderson is the CEO and Founder of Alloy Therapeutics. Founded in 2017, the company democratizes access to drug discovery platforms and services. In our conversation, we discuss Alloy's product offering and story
Orbital Therapeutics develops RNA medicines. Founded in 2022 spinning out of Beam Therapeutics, the focus is on vaccines, immunomodulation, and protein replacement therapies. The business model is premised on collecting IP spanning different RNA modalities and delivery methods
October 31, 2023 at 3:04 PM
Orbital Therapeutics develops RNA medicines. Founded in 2022 spinning out of Beam Therapeutics, the focus is on vaccines, immunomodulation, and protein replacement therapies. The business model is premised on collecting IP spanning different RNA modalities and delivery methods
Illumina sales Illumina sales
in year one: today:
$474,000 $474,000 per hour
in year one: today:
$474,000 $474,000 per hour
October 30, 2023 at 11:45 PM
Illumina sales Illumina sales
in year one: today:
$474,000 $474,000 per hour
in year one: today:
$474,000 $474,000 per hour
Scipher Medicine is a precision immunology company that matches patients with the most effective therapy for them. Developing PrismRA, a blood test that analyzes a patient's molecular signature to identify who is unlikely to respond to TNFi therapy so they can be prescribed an alternative
October 30, 2023 at 2:25 PM
Scipher Medicine is a precision immunology company that matches patients with the most effective therapy for them. Developing PrismRA, a blood test that analyzes a patient's molecular signature to identify who is unlikely to respond to TNFi therapy so they can be prescribed an alternative
Iambic Therapeutics, previously known as Entos is a drug discovery company that uses physics-based AI algorithms and high-throughput experimentation to optimize drug candidates and profiles
October 29, 2023 at 4:15 PM
Iambic Therapeutics, previously known as Entos is a drug discovery company that uses physics-based AI algorithms and high-throughput experimentation to optimize drug candidates and profiles
Dren Bio develops antibody therapies for cancer and autoimmunity. Focusing on biologics designed to selectively target and eliminate pathogenic cells and agents. Founded in 2019, their pipeline is made up of two drug discovery programs
October 27, 2023 at 12:06 AM
Dren Bio develops antibody therapies for cancer and autoimmunity. Focusing on biologics designed to selectively target and eliminate pathogenic cells and agents. Founded in 2019, their pipeline is made up of two drug discovery programs
Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity www.nature.com/articles/s41...
September 28, 2023 at 5:35 PM
Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity www.nature.com/articles/s41...
Reposted by Axial
Scientist Stories: Terry Orr-Weaver, Cell Division and Chromosome Segregation youtu.be/4OHiHK4GlSE
September 28, 2023 at 5:34 PM
Scientist Stories: Terry Orr-Weaver, Cell Division and Chromosome Segregation youtu.be/4OHiHK4GlSE
Hypoimmune induced pluripotent stem cell–derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice www.pnas.org/doi/abs/10.1...
September 20, 2023 at 4:38 PM
Hypoimmune induced pluripotent stem cell–derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice www.pnas.org/doi/abs/10.1...
Reposted by Axial
Scientist Stories: Sonja Schrepfer, The Future of Stem Cells and Hypoimmune Cell Therapies youtu.be/6sthpRhMZhg
September 20, 2023 at 4:37 PM
Scientist Stories: Sonja Schrepfer, The Future of Stem Cells and Hypoimmune Cell Therapies youtu.be/6sthpRhMZhg
Scientist Stories: Akiko Iwasaki, Immunology and Antibodies youtu.be/1gFzmoCr3Vk
September 19, 2023 at 4:44 PM
Scientist Stories: Akiko Iwasaki, Immunology and Antibodies youtu.be/1gFzmoCr3Vk
Reposted by Axial
Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins www.nature.com/articles/s41...
September 19, 2023 at 4:43 PM
Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins www.nature.com/articles/s41...
Scientist Stories: Matthias Mann, Single Cell Proteomics and Precision Medicine youtu.be/yygFYaCpQA4
September 15, 2023 at 4:35 PM
Scientist Stories: Matthias Mann, Single Cell Proteomics and Precision Medicine youtu.be/yygFYaCpQA4
Reposted by Axial
Deep Visual Proteomics defines single-cell identity and heterogeneity www.nature.com/articles/s41...
September 15, 2023 at 4:34 PM
Deep Visual Proteomics defines single-cell identity and heterogeneity www.nature.com/articles/s41...
Geometric deep learning of RNA structure www.science.org/doi/10.1126/...
September 14, 2023 at 5:16 PM
Geometric deep learning of RNA structure www.science.org/doi/10.1126/...
Reposted by Axial
Founder Stories: Tassos Gianakakos, CEO of MyoKardia youtu.be/Haa6ORz__ig
September 14, 2023 at 5:16 PM
Founder Stories: Tassos Gianakakos, CEO of MyoKardia youtu.be/Haa6ORz__ig
Scientist Stories: Siddhartha Mukherjee, New Horizons in Cell Therapy for Cancer youtu.be/tDI3wl1KSxc
September 13, 2023 at 8:50 PM
Scientist Stories: Siddhartha Mukherjee, New Horizons in Cell Therapy for Cancer youtu.be/tDI3wl1KSxc
Reposted by Axial
The human disease gene LYSET is essential for lysosomal enzyme transport and viral infection www.science.org/doi/10.1126/...
September 13, 2023 at 8:49 PM
The human disease gene LYSET is essential for lysosomal enzyme transport and viral infection www.science.org/doi/10.1126/...
Worth a Read: 'Biotech Models: Virtual Reality vs Virtual Mythology' lifescivc.com/2011/11/virt...
September 13, 2023 at 3:57 AM
Worth a Read: 'Biotech Models: Virtual Reality vs Virtual Mythology' lifescivc.com/2011/11/virt...
Reposted by Axial
"It's not enough what I did in the past - there is also the future"
- Rita Levi-Montalcini, Nobel Prize winner for discovering nerve growth factor
- Rita Levi-Montalcini, Nobel Prize winner for discovering nerve growth factor
September 13, 2023 at 3:57 AM
"It's not enough what I did in the past - there is also the future"
- Rita Levi-Montalcini, Nobel Prize winner for discovering nerve growth factor
- Rita Levi-Montalcini, Nobel Prize winner for discovering nerve growth factor
Scientist Stories: Vamsi Mootha, Mitochondrial Diseases and Function youtu.be/b6kpnLwmd9I
September 12, 2023 at 3:41 PM
Scientist Stories: Vamsi Mootha, Mitochondrial Diseases and Function youtu.be/b6kpnLwmd9I
Reposted by Axial
KRAS is vulnerable to reversible switch-II pocket engagement in cells www.nature.com/articles/s41...
September 12, 2023 at 3:40 PM
KRAS is vulnerable to reversible switch-II pocket engagement in cells www.nature.com/articles/s41...
M4205, a selective KIT inhibitor. Developed by Merck
KIT is a class III receptor tyrosine kinase. And difficult to target effectively due to its high propensity for both mutations in the KIT gene, and secondary mutations within the ATP-binding pocket
pubs.acs.org/doi/10.1021/...
KIT is a class III receptor tyrosine kinase. And difficult to target effectively due to its high propensity for both mutations in the KIT gene, and secondary mutations within the ATP-binding pocket
pubs.acs.org/doi/10.1021/...
September 11, 2023 at 11:14 PM
M4205, a selective KIT inhibitor. Developed by Merck
KIT is a class III receptor tyrosine kinase. And difficult to target effectively due to its high propensity for both mutations in the KIT gene, and secondary mutations within the ATP-binding pocket
pubs.acs.org/doi/10.1021/...
KIT is a class III receptor tyrosine kinase. And difficult to target effectively due to its high propensity for both mutations in the KIT gene, and secondary mutations within the ATP-binding pocket
pubs.acs.org/doi/10.1021/...
Reposted by Axial
"We believe that the last person in the door is just as important as the first. We consciously reject the German model for the Silicon Valley model. We want the guy on the loading dock to be thinking about clinical programs."
- Joshua Boger, Founder & CEO of Vertex Pharmaceuticals
- Joshua Boger, Founder & CEO of Vertex Pharmaceuticals
September 11, 2023 at 11:13 PM
"We believe that the last person in the door is just as important as the first. We consciously reject the German model for the Silicon Valley model. We want the guy on the loading dock to be thinking about clinical programs."
- Joshua Boger, Founder & CEO of Vertex Pharmaceuticals
- Joshua Boger, Founder & CEO of Vertex Pharmaceuticals